Konstantinos Xynos, an officer of Replimune Group Inc., filed a Form 144 notice on November 19, 2026, proposing the sale of 83,758 shares of Replimune common stock through J.P. Morgan Securities LLC on Nasdaq.
Key Highlights
- Proposed sale: 83,758 shares of Replimune Group Inc. common stock with an aggregate market value of $1,659,246, according to the filing.
- Seller: Konstantinos Xynos, identified in the filing as an officer of Replimune Group Inc.
- Broker: J.P. Morgan Securities LLC, 270 Park Avenue, 10th Floor, New York, NY 10017, is named as the executing broker.
- Approximate sale date: November 19, 2026, as stated in the filing.
- Shares outstanding: 94,800,404 shares of common stock were reported outstanding at the time of filing.
- 10b5-1 plan: The filing indicates a Rule 10b5-1 plan or instruction was adopted on August 20, 2026.
- No sales in prior 3 months: The filing reports nothing to disclose under the securities sold during the past 3 months section.
Replimune Officer Proposes Rule 144 Share Sale Sourced from RSU Vesting
According to the Form 144 filed with the U.S. Securities and Exchange Commission, Konstantinos Xynos, an officer of Replimune Group Inc. (NASDAQ:REPL), intends to sell 83,758 shares of the company's common stock. The filing lists an aggregate market value of $1,659,246 for the proposed sale, against a reported total of 94,800,404 shares outstanding. J.P. Morgan Securities LLC is identified as the named broker for the transaction.
The filing discloses that the shares proposed for sale were acquired through multiple restricted stock unit (RSU) vesting events sourced from the issuer as compensation. The acquisition dates and share amounts listed are: 18,177 shares on November 15, 2026; 9,629 shares on November 15, 2024; 9,627 shares on November 15, 2025; 12,964 shares on May 15, 2025; 18,143 shares on May 15, 2026; and 15,218 shares on August 7, 2026. All tranches are described as "Restricted Stock Units" received as compensation from the issuer.
The filing notes that the Rule 10b5-1 plan or trading instruction underlying the proposed sale was adopted on August 20, 2026. By signing the notice, the filer represented, as of the plan adoption date, that no material adverse information regarding the current and prospective operations of the issuer that had not been publicly disclosed was known to the person for whose account the securities are to be sold. No securities sales by Xynos during the prior three months were reported in the filing.
What Was Disclosed
Konstantinos Xynos, an officer of Replimune Group Inc., filed a Form 144 notice proposing to sell 83,758 shares of common stock with an aggregate market value of $1,659,246, acquired via RSU vesting events, under a Rule 10b5-1 plan adopted August 20, 2026.




Please wait processing your request...